|
| |
exelixis com Pages on BioPortfolio:
Biotechnology News Exelixis Search
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory.
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...
|
BioPortfolio - Exelixis
Exelixis - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/4024-Exelixis.html...
|
Biotechnology News GM crop byetta. amln. icahn. amylin. kliff ...
21 Nov 2008 ... Exelixis Announces December 2 Webcast of Presentation at the Piper ... Scangos, PhD, President and Chief Executive Officer of Exelixis, ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...
|
BioPortfolio - Exelixis - Profile
A Broad and Expanding Pipeline At Exelixis, we are committed to making a meaningful ... Based in South San Francisco, California, Exelixis has over 550
...
http://www.bioportfolio.com/biocorporate/4024-Exelixis.pdf...
|
Biotechnology News liver lxr. exelixi. cuss. squibb. bristol. myer ...
Exelixis Research Collaboration With Bristol-Myers Squibb Extended ... Exelixis extends liver research pact with Bristol-Myers Exelixis, Inc. ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...
|
BioPortfolio - exelixis.com
exelixis.com - BioPortfolio. ... Exelixis - Entry on Bioportfolio's Biocorporate Database. ... Exelixis extends liver research pact with Bristol-Myers . ...
http://www.bioportfolio.com/search/__exelixis.com_.html...
|
Biotechnology News Multiple Endocrine Neoplasia Endocrine mtc ...
Charles Butler, 650-837-7277 Senior Director Corporate Communications & Investor Relations cbutler@exelixis.com Soleil Harrison, 650-837-7012 Senior Manager ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...
|
BioPortfolio - exelixis.com e-mail address
Exelixis Describes the Discovery of Novel Cancer Targets at AACR . ... A Broad and Expanding Pipeline At Exelixis, we are committed to making a meaningful ...
http://www.bioportfolio.com/search/__exelixis.com__e-mail_ad...
|
Biotechnology News Multiple Endocrine Neoplasia Endocrine Search
Exelixis Reports Encouraging Phase 1 Data for XL184 at EORTC-NCI-AACR Symposium ... Exelixis, Inc. (Nasdaq:EXEL) today reported encouraging new data from an ...
http://www.bioportfolio.co.uk/Multiple%20Endocrine%20Neoplas...
|
Nasdaq Biotechnology companies Epoch to Exelixis
BioPortfolio the comprehensive website for data, information, search engine and services on biotechnology, pharmaceutical and healthcare research, ...
http://www.bioportfolio.com/nasdaq/nasdaq_ebio_exel.htm...
|
Results from other life science and pharmaceutical sites:
Exelixis-an integrated drug discovery and development company ...
Exelixis is an integrated drug discovery and development company. Our primary mission is to improve patient care by developing proprietary human ...
http://www.exelixis.com/...
|
Exelixis, Inc. Research Collaboration With Bristol-Myers Squibb ...
6 Nov 2008 ... “Exelixis and Bristol-Myers Squibb have a history of working efficiently and productively together in both oncology and cardiovascular ...
http://www.biospace.com/news_story.aspx?NewsEntityId=116106...
|
Exelixis-an integrated drug discovery and development company ...
Vice President, Plant Biotechnology, Exelixis Plant Sciences ... has served as a director and as Exelixis' President and Chief Executive Officer since ...
http://www.exelixis.com/media_management.shtml...
|
Exelixis Announces December 2 Webcast of Presentation at the Piper ...
Exelixis Announces December 2 Webcast of Presentation at the Piper Jaffray 20th Annual Health Care Conference. - SOUTH SAN FRANCISCO, Calif.
http://biz.yahoo.com/bw/081121/20081121005719.html?.v=1...
|
Exelixis-an integrated drug discovery and development company ...
Information about ongoing clinical trials of Exelixis' investigational product candidates is available at ClinicalTrials.gov, a service of the U.S. National
...
http://www.exelixis.com/pipeline_xl844.shtml...
|
Exelixis, Inc. Release: Helsinn Healthcare SA To Discontinue ...
16 /PRNewswire/ -- Exelixis, Inc. today announced that its licensee Helsinn Healthcare SA has discontinued enrollment of new patients in the becatecarin ...
http://www.biospace.com/news_story.aspx?NewsEntityId=37598...
|
About Exelixis
Pursuant to a product development and commercialization agreement between Exelixis and GlaxoSmithKline, GlaxoSmithKline has the option, after completion
of ...
http://www.exelixis.com/downloads/Corporate_Backgrounder.pdf...
|
Exelixis, Inc. Says GlaxoSmithKline Collaboration to End - News ...
23 Oct 2008 ... GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=114041...
|
Phase 2 trials of XL647 are ongoing for the following: >
Pursuant to a product development and commercialization agreement between Exelixis and GlaxoSmithKline, GlaxoSmithKline has exercised its option to
further ...
http://www.exelixis.com/downloads/Compound_Backgrounders.pdf...
|
Exelixis Announces October 30 Webcast of Presentation at the 7th ...
Exelixis Announces October 30 Webcast of Presentation at the 7th Annual BIO Investor Forum. - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis ...
http://biz.yahoo.com/bw/081028/20081028006873.html?.v=1...
|
|
